Table Graph
      published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsTOCOVID, 0 0.99 [0.02; 50.02] 0.99[0.02; 50.02]TOCOVID, 010%270NAnot evaluable death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] 0.97[0.50; 1.88]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] TOCOVID, 0 0.99 [0.02; 50.02] 1.46[0.42; 5.04]BACC Bay Tocilizumab Trial, 2020, TOCOVID, 020%512lownot evaluable clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] 1.11[0.59; 2.09]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] 1.06[0.80; 1.41]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable clinical improvement (time to event analysis only)detailed resultssarimulab phase 2 low dose, 0 0.96 [0.53; 1.73] 0.96[0.53; 1.73]sarimulab phase 2 low dose, 010%247NAnot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] 0.83[0.38; 1.81]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] 1.21[0.58; 2.53]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-20 00:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons